Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

NCT05423691 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: CK0804

Sponsor

Cellenkos, Inc.